Back to Search Start Over

The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease.

Authors :
Barden AE
Shinde S
Burke V
Puddey IB
Beilin LJ
Irish AB
Watts GF
Mori TA
Source :
Prostaglandins & other lipid mediators [Prostaglandins Other Lipid Mediat] 2018 May; Vol. 136, pp. 1-8. Date of Electronic Publication: 2018 Mar 22.
Publication Year :
2018

Abstract

Background: Neutrophils release leukotriene (LT)B <subscript>4</subscript> and myeloperoxidase (MPO) that may be important mediators of chronic inflammation in chronic kidney disease (CKD). The n-3 fatty acids (n-3 FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have the potential to attenuate inflammation through production of LTB <subscript>5</subscript> and the Specialized Proresolving Lipid Mediators (SPM) that promote the resolution of inflammation. In animal models, coenzyme Q10 (CoQ) also attenuates inflammation by reducing MPO and LTB <subscript>4</subscript> .<br />Objective: This study evaluated the independent and combined effects of n-3 FA and CoQ supplementation on neutrophil leukotrienes, the pro-inflammatory eicosanoid 5-hydroxyeicosatetraenoic acid (5-HETE), SPM, and plasma MPO, in patients with CKD.<br />Design: In a double-blind, placebo-controlled intervention of factorial design, 85 patients with CKD were randomized to either n-3 FA (4 g), CoQ (200 mg), both supplements, or control (4 g olive oil), daily for 8 weeks. Plasma MPO and calcium ionophore-stimulated neutrophil release of LTs, 5-HETE and SPM were measured at baseline and after 8 weeks.<br />Results: Seventy four patients completed the intervention. n-3 FA, but not CoQ, significantly increased neutrophil LTB <subscript>5</subscript> (P < 0.0001) and the SPM 18-hydroxyeicosapentaenoic acid (18-HEPE), resolvin E1 (RvE1), resolvin E2 (RvE2) and resolvin E3 (RvE3) that derive from EPA, as well as 17-hydroxydocosahexaenoic acid (17-HDHA) and resolvin D5 (RvD5) that derive from DHA (all P < 0.01). Neutrophil LTB4 and its metabolites, and 5-HETE were not significantly altered by n-3 FA or CoQ. Plasma MPO was significantly reduced with n-3 FA alone (P = 0.013) but not when given in combination with CoQ.<br />Conclusion: n-3 FA supplementation in patients with CKD leads to increased neutrophil release of LTB <subscript>5</subscript> and several SPM, as well as a reduction in plasma MPO that may have important implications for limiting chronic inflammation.<br /> (Copyright © 2018 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1098-8823
Volume :
136
Database :
MEDLINE
Journal :
Prostaglandins & other lipid mediators
Publication Type :
Academic Journal
Accession number :
29577973
Full Text :
https://doi.org/10.1016/j.prostaglandins.2018.03.002